Table 2.
Treatment-emergent adverse events (AEs) by preferred term
| GLP-1-RA group (n = 13) | |
|---|---|
| Any AEs | 9 (69.2) |
| Mild AEs | 1 (7.7) |
| Moderate AEs | 8 (61.5) |
| Severe AEs | 0 (0.0) |
| AEs leading to premature treatment discontinuation | 0 (0.0) |
| AEs occurring in 5% of patients | |
| Nausea | 9 (69.2) |
| Mild | 1 (7.7) |
| Moderate | 8 (61.5) |
| Decreased appetite | 2 (15.4) |
| Increased lipase | 3 (23.1) |
| Mild (< 1.5 ULN) | 3 (23.1) |
| Diarrhea | 1 (7.7) |
| Mild | 1 (7.7) |
| Hypoglycemia | 1 (7.7) |
| Mild (55–70 mg/dL) | 1 (7.7) |
| Increased ALAT | 1 (7.7) |
| Mild (< 3.0 ULN) | 1 (7.7) |
| Dyspepsia | 1 (7.7) |
| Mild | 1 (7.7) |
ALAT Alanine aminotransferase, GLP-1 Glucagon-like peptide-1, ULN Upper limit of normal